NASUS PHARMA LTD NSRX

US Healthcare Pharmaceutical Preparations
$3.50
-0.4%
52w: $2.01 – $9.15

Latest 13F among current holders filed 1 month ago (May 15, 2026)

Price — last 12 months

research preview data
2.015.589.15
Aug 13, 2025 Jul 2, 2026
Institutional holders
9
+7 QoQ
13F value
$4.8M
+22081.8% QoQ
Smart-money holders
3
signal tier ≥ 2
New smart buyers
3
Q1 2026

Institutional value by quarter

$22K
Q3 2025
$22K
Q4 2025
$4.8M
Q1 2026

Number of holders

2
Q3 2025
2
Q4 2025
9
Q1 2026

Who owns NSRX?

Q1 2026 filings
FundTypeSharesValue% of fundChange
Balyasny Asset Management L.P. Multistrat pod898.5K$2.0M0.0%New
Cable Car Capital, LP ★2Fundamental diversified602.0K$1.3M0.6%New
Velan Capital Investment Management LP ★2Fundamental concentrated359.4K$798K0.5%New
Hudson Bay Capital Management LP Multistrat pod134.8K$299K0.0%New
Bleichroeder LP Other89.8K$199K0.0%New
Empery Asset Management, LP ★2Fundamental concentrated45.8K$102K0.1%New
HRT FINANCIAL LP Diversified mechanical38.9K$86K0.0%New
UBS Group AG Bank broker3.1K$7K0.0%+718.5%
MORGAN STANLEY Bank broker2.0K$4K0.0%Held

Exits are not a bearish signal: our backtest shows stocks specialists exit keep outperforming for 3+ quarters — selling usually means profit-taking, not a forecast.